Message from the President

Kazutaka Kikuta, Director of Tochigi Cancer Biobank

Kazuki Kikuta, Director of Biobank Center

The remarkable advances in cancer treatment and research have made cancer incurable and curable for some types of cancer. However, the overall 5-year survival rate for cancer is still about 60%, and there are still a lot of cancer types that are difficult to treat. Therefore, cancer research needs to continue to be promoted for further advances in cancer treatment.
The hospital established the Tochigi Cancer Biobank to promote cancer research and develop new treatments for cancer. In particular, we are focusing our efforts on the accumulation of samples of rare cancers, liver, gallbladder, pancreas, and other refractory cancers. These biobank samples can be looked at in conjunction with medical information to identify abnormalities in the molecular mechanisms involved in the development and progression of cancer and to identify biomarkers and therapeutic targets.
The BioBank aims to contribute to the development of new cancer therapies by collaborating with clinicians, researchers, companies, and academia, and by providing biobank samples to all cancer research centers around the world. Our desire is that our BioBank be used by many people for the treatment of cancer in the next era. I hope that many people will use the BioBank. All for patients now suffering from cancer. And for future cancer patients.

Kazutaka Kikuta, Director of the Tochigi Cancer Biobank Biobank Center

Iwao Ozawa, Director of Tochigi Cancer Center

Iwao Ozawa, Director of Biobank Center

The Tochigi Cancer Center, an independent administrative institution, has contributed to improving the survival rate of patients through medical treatment using a variety of medical technologies.
However, there are many carcinomas that have not yet been cured, such as rare cancers such as sarcoma and pancreatic cancer.
The Center's role as a regional cancer center for cancer with no cure potential,

  • Providing surgery and blood samples as well as clinical information to basic researchers
  • Cooperation in drug discovery by pharmaceutical companies (provision of samples and clinical information, including clinical trials)
  • Translational research (clinical application of academia research results)
  • Provision of samples to establish a testing system for liquid biopsy
  • Genome analysis
  • Clinical Trials
It is possible. We believe that it is extremely important to apply cancer research and its results, which are expected to progress rapidly in the future, to clinical applications, and that this is a role that the Center must play.
The Tochigi CancerIobank Center was established to efficiently fulfill the above roles. In addition to research, we will make it available for genomic tests that patients need to treat their cancer.
It is also possible to conduct joint research at the Center Laboratories. We believe that it is possible to provide samples after adding detailed clinical information unique to cancer centers, so we would like you to contact a researcher or a company that is interested in it. In the future, we plan to gradually increase the number of samples for carcinomas as well as samples for carcinomas.

Iwao Ozawa, Director of the Tochigi Cancer Center